Latest Regulatory Milestones News

Neuren Pharmaceuticals has approved a significant long-term equity incentive plan tied to critical clinical and regulatory milestones for its drug candidate NNZ-2591, reinforcing management’s commitment to shareholder value.

Gold Road Resources has secured a crucial regulatory green light as the Foreign Investment Review Board approves Gold Fields’ acquisition scheme. The deal now moves closer to shareholder and court approvals.

EMVision Medical Devices has enhanced its AI-powered stroke diagnostic algorithm, achieving a notable 95% sensitivity and 80% specificity in recent tests. This progress sets the stage for upcoming pivotal trials and regulatory milestones.

Janus Electric Holdings Limited will have its trading suspension lifted and resume quotation on the ASX from 21 May 2025 after meeting key listing requirements.

Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.

Southern Palladium has secured Environmental Authorisation for its Bengwenyama PGM Project, a crucial step toward mining rights and project development. The company is also refining a phased, lower-capital approach to unlock value and improve financeability.

Arizona Lithium has achieved a landmark regulatory approval for Phase 1 production at its Prairie Lithium Project, marking the first lithium brine operation sanctioned in Saskatchewan. Updated drilling and modeling have significantly expanded the project's resource base and production potential.

Manuka Resources’ Taranaki VTM Project has cleared a key regulatory hurdle, moving forward in New Zealand’s Fast-track Approvals Process with promising economic and environmental prospects.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Anson Resources has gained regulatory approval to re-enter a historic well at its Green River Lithium Project, aiming to deepen the reservoir and advance its lithium resource definition. This move sets the stage for a critical feasibility study that could underpin future lithium production.

Paradigm Biopharmaceuticals has secured centralised US ethics approval for its pivotal Phase 3 trial of injectable pentosan polysulfate sodium (iPPS) targeting moderate to severe knee osteoarthritis, setting the stage for patient enrolment in Q3 2025.

Estrella Resources has upgraded four reconnaissance permits to exploration licenses in Timor-Leste, significantly enlarging its landholding and enabling advanced exploration activities targeting manganese and limestone deposits.